Revolutionizing Cancer Treatment in India: IIT-B Startup Secures Government Approval for Pioneering CAR-T Therapy
IIT Bombay-incubated startup, ImmunoACT, has achieved a significant milestone by receiving the Central Drugs Standard Control Organisation’s approval for India’s first CAR-T cell therapy. This groundbreaking therapy is backed by Laurus Labs and is named NexCAR19. It is specifically designed to combat certain types of blood cancers, including leukemia. Prior to this development, Indian patients who sought this therapy typically traveled to the US, where the treatment costs exceeded ₹3.3 crore.
Key Insights:
- Innovation in India: The approval of NexCAR19 showcases the advancements and capabilities of Indian startups in the medical and biotech sectors. It also emphasizes the importance of homegrown solutions to address critical health challenges.
- Affordability and Accessibility: With the introduction of this therapy in India, patients will no longer need to travel abroad, potentially making the treatment more accessible and affordable.
- Potential Impact on Healthcare: The success of NexCAR19 could pave the way for further research and development in the field of cancer treatment in India, leading to more innovative solutions in the future.
